Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

435 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase I study of dose-escalated busulfan with fludarabine and alemtuzumab as conditioning for allogeneic hematopoietic stem cell transplant: reduced clearance at high doses and occurrence of late sinusoidal obstruction syndrome/veno-occlusive disease.
O'Donnell PH, Artz AS, Undevia SD, Pai RK, Del Cerro P, Horowitz S, Godley LA, Hart J, Innocenti F, Larson RA, Odenike OM, Stock W, Van Besien K. O'Donnell PH, et al. Among authors: innocenti f. Leuk Lymphoma. 2010 Dec;51(12):2240-9. doi: 10.3109/10428194.2010.520773. Epub 2010 Oct 4. Leuk Lymphoma. 2010. PMID: 20919852 Free PMC article. Clinical Trial.
R(+)XK469 inhibits hydroxylation of S-warfarin by CYP2C9.
Yong WP, Kim TW, Undevia SD, Innocenti F, Ratain MJ. Yong WP, et al. Among authors: innocenti f. Eur J Cancer. 2009 Jul;45(11):1904-8. doi: 10.1016/j.ejca.2009.04.032. Epub 2009 May 21. Eur J Cancer. 2009. PMID: 19464879 Free PMC article.
A pharmacogenetic study of aldehyde oxidase I in patients treated with XK469.
Ramírez J, Kim TW, Liu W, Myers JL, Mirkov S, Owzar K, Watson D, Mulkey F, Gamazon ER, Stock W, Undevia S, Innocenti F, Ratain MJ. Ramírez J, et al. Among authors: innocenti f. Pharmacogenet Genomics. 2014 Feb;24(2):129-32. doi: 10.1097/FPC.0000000000000023. Pharmacogenet Genomics. 2014. PMID: 24300566 Free PMC article.
Dose-finding and pharmacokinetic study to optimize the dosing of irinotecan according to the UGT1A1 genotype of patients with cancer.
Innocenti F, Schilsky RL, Ramírez J, Janisch L, Undevia S, House LK, Das S, Wu K, Turcich M, Marsh R, Karrison T, Maitland ML, Salgia R, Ratain MJ. Innocenti F, et al. J Clin Oncol. 2014 Aug 1;32(22):2328-34. doi: 10.1200/JCO.2014.55.2307. Epub 2014 Jun 23. J Clin Oncol. 2014. PMID: 24958824 Free PMC article. Clinical Trial.
Individualizing dosing of irinotecan.
Ratain MJ, Innocenti F. Ratain MJ, et al. Among authors: innocenti f. Clin Cancer Res. 2010 Jan 15;16(2):371-2. doi: 10.1158/1078-0432.CCR-09-2936. Epub 2010 Jan 12. Clin Cancer Res. 2010. PMID: 20068075
435 results